Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, Innovative Medicine, R&D | May 01, 2026 | May 04, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date May 01, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,911 |
Ending reported balance
After 2026-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Exercise / conversion · Acquired 25,255 · Balance 35,913 F1: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Row 2 · 2026-05-01 · Tax withholding · Disposed 11,002 · Balance 24,911 F2: Shares withheld for payment of taxes upon vesting of RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Exercise / conversion · Disposed 25,255 · Balance 0 F1: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting.
F2: Shares withheld for payment of taxes upon vesting of RSUs.
MADRIGAL PHARMACEUTICALS, INC.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 647 |
Reported balance
After 2026-08-15 transaction · row 1
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 647 · Balance 647 F1: Represents a grant of restricted stock units which vest as to 50% of the shares on each of August 15, 2027 and August 15, 2028, provided the Reporting Person continues in service with the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $507.56 · Expires 2036-08-15 | Direct | 1,078 |
Reported balance
After 2026-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-15 · Grant · Acquired 1,078 · Balance 1,078 F2: The option vests as to 50% of the shares on the first anniversary of the date of grant (August 15, 2027), and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period for four successive three-month periods, provided the Reporting Person continues in service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest as to 50% of the shares on each of August 15, 2027 and August 15, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
F2: The option vests as to 50% of the shares on the first anniversary of the date of grant (August 15, 2027), and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period for four successive three-month periods, provided the Reporting Person continues in service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 21:10 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,078 | $0.00 Strike: $507.56 | $0.00 |
DisclosureSEC source: 0001628280-26-057751 · wk-form4_1787087423.xml · derivative · entry 2 REED JOHN C · CIK 0001181561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,078 Underlying: Common Stock · 1,078 shares Expires 2036-08-15 F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of the date of grant (August 15, 2027), and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period for four successive three-month periods, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:10 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 647 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-057751 · wk-form4_1787087423.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647 F1 · kind: Represents a grant of restricted stock units which vest as to 50% of the shares on each of August 15, 2027 and August 15, 2028, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:58 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000115 · wk-form4_1777928336.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:58 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 11,002 | $229.85 | $2,528,809.70 |
DisclosureSEC source: 0000200406-26-000115 · wk-form4_1777928336.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,911 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:58 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000115 · wk-form4_1777928336.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 29,927 | $0.00 Strike: $156.15 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · derivative · entry 15 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,854 Underlying: Common Stock · 29,927 shares Expires 2035-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 21,721 | $0.00 Strike: $157.92 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · derivative · entry 14 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,721 Underlying: Common Stock · 21,721 shares Expires 2034-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 2,283 | $243.00 | $554,769.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 9 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,658 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 29,927 | $243.00 | $7,272,261.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 8 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,941 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 29,927 | $156.15 | $4,673,101.05 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 7 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 21,721 | $243.00 | $5,278,203.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 6 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,941 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 21,721 | $157.92 | $3,430,180.32 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 5 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,546 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · derivative · entry 13 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,546 Underlying: Common Stock · 3,546 shares Expires not disclosed F6 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F6 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F6 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F4 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 49,382 | $0.00 Strike: $243.45 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · derivative · entry 12 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,382 Underlying: Common Stock · 49,382 shares Expires 2036-02-15 F5 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · derivative · entry 11 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,692 Underlying: Common Stock · 1,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F3 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F3 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F4 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,349 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · derivative · entry 10 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,349 Underlying: Common Stock · 1,349 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F4 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 528 | $243.45 | $128,541.60 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 4 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,941 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 385 | $243.45 | $93,728.25 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,622 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,349 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000039 · wk-form4_1771467119.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 23:13 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 21,721 | $157.92 Strike: $157.92 | $3,430,180.32 |
DisclosureSEC source: 0000200406-25-000204 · wk-form4_1761002033.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,442 Underlying: Common Stock · 21,721 shares Expires 2034-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 23:13 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 21,721 | $192.71 | $4,185,793.09 |
DisclosureSEC source: 0000200406-25-000204 · wk-form4_1761002033.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,658 F1 · price: This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 23:13 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 21,721 | $157.92 | $3,430,180.32 |
DisclosureSEC source: 0000200406-25-000204 · wk-form4_1761002033.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:12 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 19,137 | $163.55 | $3,129,829.56 |
DisclosureSEC source: 0000200406-25-000172 · wk-form4_1752869553.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,658 F1 · price: This transaction was executed in multiple trades at prices ranging from $163.52 to $163.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:10 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000143 · wk-form4_1746479407.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,255 Underlying: Common Stock · 25,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:10 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 11,002 | $156.31 | $1,719,722.62 |
DisclosureSEC source: 0000200406-25-000143 · wk-form4_1746479407.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,795 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| May 01, 2025 Filed May 5, 2025 21:10 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000143 · wk-form4_1746479407.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 385 | $156.15 | $60,117.75 |
DisclosureSEC source: 0000200406-25-000054 · wk-form4_1739931099.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,542 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000054 · wk-form4_1739931099.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,698 Underlying: Common Stock · 1,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F3 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000054 · wk-form4_1739931099.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 22:29 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 5,539 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000074 · wk-form4_1740004157.xml · derivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,539 Underlying: Common Stock · 5,539 shares Expires not disclosed F2 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F2 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 22:29 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 89,781 | $0.00 Strike: $156.15 | $0.00 |
DisclosureSEC source: 0000200406-25-000074 · wk-form4_1740004157.xml · derivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,781 Underlying: Common Stock · 89,781 shares Expires 2035-02-15 F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 22,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005567 · doc4.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,510 Underlying: Common Stock · 22,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. F1 · derivative.exercise_date: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 10,984 | $144.59 | $1,588,176.56 |
DisclosureSEC source: 0001225208-24-005567 · doc4.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,577 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 22,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005567 · doc4.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. Read SEC document |
| May 01, 2024 Filed Oct 31, 2024 21:57 UTC Amendment | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-24-000098 · wk-form4a_1730411857.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,510 Underlying: Common Stock · 25,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. F1 · derivative.exercise_date: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. Read SEC document |
| May 01, 2024 Filed Oct 31, 2024 21:57 UTC Amendment | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 10,984 | $144.59 | $1,588,176.56 |
DisclosureSEC source: 0000200406-24-000098 · wk-form4a_1730411857.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,577 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| May 01, 2024 Filed Oct 31, 2024 21:57 UTC Amendment | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-24-000098 · wk-form4a_1730411857.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:55 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 4,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002534 · doc4.xml · derivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,048 Underlying: Common Stock · 4,048 shares Expires 2034-02-15 F2 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to acquire one share of Common Stock. F3 · derivative.exercise_date: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:55 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 65,163 | $0.00 Strike: $157.92 | $0.00 |
DisclosureSEC source: 0001225208-24-002534 · doc4.xml · derivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,163 Underlying: Common Stock · 65,163 shares Expires 2034-02-15 F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 01, 2023 Filed May 2, 2023 21:21 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 75,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005258 · doc4.xml · derivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Pharmaceuticals R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,765 Underlying: Common Stock · 75,765 shares Expires not disclosed F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to acquire one share of Common Stock. F2 · derivative.exercise_date: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: The Restricted Share Units vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.